Zai Lab announced dosing of the first patient in the Company’s Phase 3 China registration trial of ZL-2306 for first-line maintenance therapy of patients with platinum-responsive ovarian cancer. ZL-2306 is a highly potent and selective oral, once-daily small molecule poly polymerase 1/2, or PARP 1/2, inhibitor with the potential to be a first-in-class Category 1 drug in China for treatment across multiple solid tumor types. In September 2017, Zai Lab commenced its Phase 3 China registration trial of ZL-2306 as a second-line maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer. The Company is also currently preparing for its Phase 3 registration trial of ZL-2306 for small cell lung cancer, which it anticipates to commence by mid-2018. Zai Lab’s Phase 3 China registration study announced today is a 2:1 randomized, double-blind, placebo-controlled, multi-center trial to evaluate the efficacy and safety of ZL-2306 as maintenance therapy following first-line platinum-based chemotherapy in patients with ovarian cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.